Skin Whitening Injections provide faster and more direct absorption compared to oral supplements, which may have reduced bioavailability
Much simpler than topical applications
Contamination due to alternative weight loss intervention (Intervention and control) Since semaglutide was first licenced for the treatment of obesity in 2021, tirzepatide, a GLP-1/GIP receptor agonist with has even greater efficacy of weight loss, has achieved FDA approval in 2023
What is this feeling, so sudden and new
Funding: This study was funded by the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Womens Hospital, Harvard Medical School, Boston, MA